Project Grant R01AI190004
Award Date
6/6/25
Completion Date
5/31/30
Dollars Obligated
$844K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This Project Grant award, in the amount of $506,530, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The primary objective of this 2-year grant is to define the mechanisms by which antibodies can block cell-to-cell transmission of alphavirus infections, such as chikungunya virus (CHIKV) and Mayaro virus (MAYV). The research will: 1) Determine how antibodies target viral envelope proteins...
This $561,538 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of neutralizing antibodies against Machupo virus, a New World arenavirus. The research aims to utilize advanced immunization techniques, a stabilized antigen, and high-throughput screening to identify and characterize antibodies targeting complementary epitopes on the virus' surface glycoprotein....
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $558,501 to support critical research into the Crimean-Congo Hemorrhagic Fever Virus (CCHFV). The primary awardee, Albert Einstein College of Medicine, is leading a collaborative effort to advance the understanding of CCHFV glycoprotein structure, assembly, and functions in viral entry, assembly, and...
This $1,486,800 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Albert Einstein College of Medicine into antibody-dependent cell-mediated cytotoxicity (ADCC) for vaccine development against herpes simplex virus (HSV). The project aims to investigate the role of TNFRSF14 signaling in promoting ADCC responses and develop new strategies for future vaccine and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $809,614 to the Icahn School of Medicine at Mount Sinai to develop broadly neutralizing human monoclonal antibodies against henipaviruses, a highly pathogenic group of viruses that cause severe respiratory and neurological diseases. The primary objective is to design novel immunogens to induce broadly...
This $598,752 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to identify and design broadly acting antibodies targeting the S2 subunit of the SARS-CoV-2 spike protein. The research project will evaluate the functional properties of these S2-targeting antibodies using neutralization assays, in vitro Fc-effector function assays, and systems serology approaches. The goal...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $318,085 to support research on the role of cell, antigen, and antibody in controlling virus infection through Fc-dependent mechanisms. The research aims to understand the molecular determinants that govern how natural killer (NK) cells control virus dissemination through antibody-dependent cellular...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $147,656 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The project aims to elucidate the mechanisms driving the development of chronic Chikungunya virus (CHIKV) arthritis, a debilitating condition affecting up to 50% of CHIKV patients. The research will define the viral reservoir in macrophages, assess mechanisms driving pro-inflammatory...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,969 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to L2 Diagnostics LLC, a for-profit biomedical research company based in Woodbridge, Connecticut. The grant is focused on evaluating a mosquito salivary protein, AGBR1, as a vaccine candidate against Chikungunya virus, which is transmitted by Aedes mosquitoes and can cause debilitating joint pain. Under this two-year...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $782,871 in funding to the University of Colorado-Denver to conduct research on the immune evasion mechanisms of arthritogenic alphavirus infections, such as Chikungunya and Ross River viruses. The key objectives of this 5-year research project are to: 1) investigate how type I interferon signaling in...